Skip to main content

Sema4 Holdings Corp. (SMFR)

New York Stock Exchange Healthcare Medical - Healthcare Information ServicesView data quality →
48.0Fair

ValueMarkers Composite Index

Top 25%#33,704 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.21
Investigate
Altman
-1.89
Distress
DCF Value
-
N/A
ROIC
-2.7%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Sema4 Holdings Corp. (SMFR) — VMCI valuation read

Sema4 Holdings Corp. sits at VMCI 48/100, with the Healthcare sector median at 50. That 2-point spread is the first thing to note on SMFR: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on SMFR are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on SMFR: SMFR trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 0.9x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

SMFR fell 1.5% over the trailing 7 days, with a -11.7% read on a 30-day basis.

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

CEO: Jason Ryan1,200 employeesUSwww.sema4.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SMFR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.